Poster Area |
Antiretroviral Therapy
Chairs: R. Maserati, P. Nasta
OP 1 Evaluation of total HIV-DNA and residual viremia in HIV-1 infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-OnE Study
|
OP 2 Durability and liver safety of InSTI-based regimens in HIV-infected patients with advanced liver fibrosis or cirrhosis: data from the ODOACRE cohort
|
OP 3 Prevalence of transmitted resistance mutations to rilpivirine and doravirine in treatment-naive patients in a large clinical and resistance database
|
OP 4 Efficacy and tolerability of bictegravir/ tenofovir alafenamide/ emtricitabine as a switch strategy in a cohort of antiretroviral therapy treatment-experienced HIV-1-infected patients
|
OP 5 Viral rebound in pts with suppressed HIV-RNA on a 2 or 3-drug regimen: a comparison
|
OP 6 Optically traceable PLGA Nanoparticles improve the ability of darunavir to cross the blood brain barrier and inhibit MMP-9. Implications for the Treatment of HIV-Associated Neurological Disorders
|
OP 7 Effectiveness and long-term durability of rilpivirine-based single tablet regimens in a large cohort of HIV-infected patients. A preliminary analysis
|
OP 8 Increase in body weight after a year of INI-exposure in a multicenter italian cohort
|
OP 9 Treatment outcome among HIV-1 infected patients who started first-line ART pending GRT results from 2015 to 2018
|
OP 10 Retrospective analysis of reasons and characteristics of switches in a cohort of women affected by HIV infection referring to D. Cotugno Hospital, Naples, period 2017-2019
|
OP 11 Assessing the feasibility of 2-drug regimens as switch strategies in a multicenter cohort
|
OP 12 Risk of failure in dual vs triple therapy in naïve HIV-patients: a meta-analysis
|
Basic Science and Immunology
Chairs: L. Butini, S. Piconi
OP 13 DAA treatment fails to restore the inflammatory profile both in HCV/HIV and in HCV infected patients
|
OP 14 Sterol metabolism modulates susceptibility to HIV-1 Infection
|
OP 15 Different amounts of activated or exhausted effector memory T cells among differentiated CD4+ or CD8+ T lymphocytes during primary, acute HIV infection
|
OP 16 HIV+ patients: modulating effects of antiretroviral therapy on cytokines' profile and microbiota composition
|
OP 17 Association between subclinical atherosclerosis and IFN-I response in HIV-1 infected patients
|
OP 18 p53/mir34a/SIRT1 loop and immune reconstitution relationship during chronic HIV infection
|
OP 19 Lower Immune Activation in Perinatally than in Horizontally HIV-Infected Adults
|
OP 20 Microbiota Composition in HIV-Positive and HIV-Exposed Uninfected Pediatric Subjects
|
OP 21 Switching to integrase inhibitors is not linked to weight increase in young adults and adolescents perinatally infected with HIV, results from a 10-years observational study
|
OP 22 An atypical case of HIV-1 elite controller: 15 years of follow up
|
Clinical HIV
Chairs: M. Borderi, A. Ruggieri
OP 23 Newly diagnosed HIV infected patients in Brescia, Northern Italy: epidemiological and clinical characteristics and possible targets of prevention and early diagnosis campaign
|
OP 24 Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in HIV-infected patients with metabolic syndrome
|
OP 25 Durability of InSTI-based regimen in geriatric people living with HIV. Data from the Italian Multicenter GEPPO Cohort
|
OP 26 Weight gain and body composition changes in people living with HIV treated with Integrase Strand Transfer Inhibitors: a longitudinal assessment with Bioimpedance Vectorial Analysis
|
OP 27 Transmitted drug resistance in newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy
|
OP 28 Same day treatment and rapid antiretroviral therapy introduction in a cohort of unselected newly-diagnosed HIV-positive individuals
|
OP 29 Changes in homeostatic model assessment for insulin resistance (HOMA-IR) index in treated HIV-1 infected people on virological suppression
|
OP 30 A descriptive analysis on dual regimens' discontinuations in a multicentre Italian cohort
|
OP 31 Virological response and resistance profile in highly treatment-experienced HIV-1 infected patients switching to dolutegravir plus boosted-darunavir in clinical practice
|
OP 32 Does rapid initiation of ART at HIV diagnosis impact on virological response and retention in care? A single center experience (Brescia, Northern Italy)
|
OP 33 Efficacy and durability of dolutegravir- or darunavir-based regimens in ART-naïve AIDS- or late-presenter patients
|
OP 34 Efficacy Safety and Tolerability of the switch from efavirenz/emtricitabine/tenofovir disoproxil on alternate days or continuous treatment to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV+ (EBONY Study)
|
Clinical HIV II
Chairs: R. Bellagamba, V. Giacomet
OP 35 Allogenic hematopoietic stem cell transplantation in HIV-positive recipients: a case series
|
OP 36 Italian survey on clinicians' approach to Latent Tubercular Infection in people living with HIV
|
OP 37 A poor immunological recovery is associated with non-AIDS-defining cancers in the era of HAART: a case-control study
|
OP 38 HPV infection in HIV+, MSM patients followed at a large HIV Clinic in Northern Italy
|
OP 39 Risk of multiple primary neoplasms and impact on survival of person living with HIV (PLWH)
|
OP 40 Development and standardization of a real time PCR for the quantification of HTLV-1 proviral load
|
OP 41 Is pretreatment HIV-1 integrase resistance increasing? A large Italian centre experience
|
OP 42 Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection
|
OP 43 Evolving epidemiology of HIV/AIDS in Campania Region, 2008-19: is HIV/AIDS population in Campania different?
|
OP 44 Impact of boosted vs unboosted antiretroviral regimen on Dolutegravir plasma and intracellular pharmacokinetics
|
Comorbidities
Chairs: F. Carli, P. Maggi, I. Maida
OP 45 Inflammatory and neurometabolite changes among patients switching away from efavirenz and their correlation with neurotoxicity: results from the sub-study of a randomized controlled trial
|
OP 46 Contribution of INSTI, BMI, physical activity or caloric intake to weight gain in PLWH
|
OP 47 Cerebrospinal Fluid CXCL13 as a marker of Intrathecal Immunoglobulin Synthesis and Immune-activation in treatment-naïve People Living with HIV
|
OP 48 Evaluation of the association between cognitive performance and HAND diagnosis with the cognitive reserve in naïve HIV-infected patients
|
OP 49 Are Low vitamin D plasma levels associated with intrathecal immuneactivation in PLWH?
|
OP 50 Gender differences in neurocognitive functions in PLWK
|
OP 51 Menopause in aging women living with HIV: changes in bone mineral density and trabecular bone score
|
OP 52 NAFLD phenotype and prevalence across the menopause spectrum in women with HIV
|
OP 53 Incidence of diabetes in a cohort of PLWH people living with HIV in Perugia
|
OP 54 Standard vs higher dose of Rifampicin in patients with tuberculosis: a meta-analysis
|
Hepatitis and Coinfections
Chairs: O. Armignacco, M. Massari, C. Sagnelli
OP 55 Rapid Detection of Mycobacterium tuberculosis DNA in pulmonary and extrapulmonary paraffinized samples by ddPCR
|
OP 56 Pharyngeal contamination is a major driver for sexually transmitted infections epidemic in Men who have Sex with Men
|
OP 57 HCV infection in PWUD: a microelimination intervention in Rome
|
OP 58 Direct-acting antiviral based treatment for HCV-infected persons who inject drugs: a multi-centre real-life study
|
OP 59 Are Non-Injecting Drug Users at risk of HCV-infection? Data from the San Patrignano cohort
|
OP 60 Real Life DAAs in a large cohort of people who use drugs with hepatitis C virus infection in Tor Vergata Hospital in Rome: adherence, efficacy and reinfections of a key population
|
OP 61 Effects of HCV eradication on liver function in haemophilic HIV/HCV co-infected patients
|
OP 62 Virological patterns of HCV-patients with failure to second generation direct-acting antivirals
|
OP 63 Advanced liver disease outcomes after Hepatitis C viral eradication according to Human Immunodeficiency Virus coinfection in PITER cohort
|
OP 64 The combination of accurate serological and virological HBV markers can help to predict the occurrence of HBV reactivation and to optimize prophylaxis duration in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases
|
OP 65 HBV and HDV infection in immigrants living in South Italy: epidemiological and virological characteristics
|
OP 66 HEV infection as an emergent public health issue: is it a concern for Italian blood donors?
|
Social Science and Prevention
Chairs: S. Babudieri, B.M. Celesia, M.G. Di Benedetto
OP 67 HIV SelfTesting: a survey of self-tests availability in Italian Pharmacies
|
OP 68 Testing MSM in cruising venues
|
OP 69 Behavioral aspects of MSM tested in community-based settings in 5 cities
|
OP 70 Pre-exposure prophylaxis in Modena: a wide spread of sexually transmitted infections among users attending the dedicated outpatient Clinic
|
OP 71 Prevalence and risk factors for HPV anal infection in PrEP users: implications for vaccination policy
|
OP 72 NEETagers for the prevention of HIV and AIDS
|
OP 73 Clinical research integrated with narrative medicine to understand living and coping with HIV: TMC114FD1HTX4011 - DIAMANTE study
|
OP 74 Women and HIV in prison setting: a data up date from the Italian ROSE network
|
OP 75 First-year experience of an HIV clinic-based stop-smoking service
|
OP 76 Psychiatric disturbances are common in PrEP users: an analysis of comorbidities and comedications in real life
|
Virology and Pharmacology
Chairs: R. Cavallo, S. Parisi
OP 77 The HIV-1 provirus excised by CRISPR/Cas9 may be integrated back into the cell genome in presence of the viral integrase
|
OP 78 Analysis of HIV latency establishment and maintenance in CD4 T cells stimulated with IL-15
|
OP 79 Phylogenetic analyses applied to the study of transmission variants and their evolution in a HIV-1 positive couple
|
OP 80 Creation of an Italian HIV DNA Network for the validation and clinical use of HIV-1 DNA quantification assays
|
OP 81 Initial characterization of elements detected and quantified exclusively on the basis of LTR region by Aptima HIV-1 Quant Dx dual-target assay in plasma of HIV-positive patients
|
OP 82 Stable total HIV-DNA after 1 year on switch to TAF-based regimens in real world data
|
OP 83 HIV-1 RNA and DNA mutational load in HTE patients with MDR virus: a tool for deciding OBR?
|
OP 84 Viral tropism does not have any impact on CD4 recovery in acute HIV infection or AIDS
|
OP 85 Antiviral effect of HIV1 tat/rev siRNA carried by nanoparticles in human CD4+ T cell line
|
OP 86 A real-life experience of vaccination strategies for HBV prevention in HIV patients
|
OP 87 A successful experience of an immunization program in HIV-positive adults
|
OP 88 Plasma exchange and dolutegravir exposure. A case report
|
Poster: Bacterial and fungal infections in immunocompromised host
P 1 A descriptive analysis of bloodstream infections in patients living with HIV in a large Italian center |
P 2 Amebic abscess of the spleen with severe sepsis and bronchial fistulisation in HIV+patient: case report |
P 3 Pneumocystis jirovecii Pneumonia in HIV-negative Patients, a Frequently Overlooked Problem: Case Series from a Large Italian Center |
P 4 Infection by Mycobacterium chimaera in two subjected undergoing cardiac surgery |
P 5 A case of persistent relapsing abdominal mycobacterial infection requiring prolonged intravenous multi-drug treatment |
Poster: Basics in viral hepatitis
P 6 Comparison of immunoassays for quantitative serum HBsAg |
P 7 Cryptic HBV replication is frequently revealed in anti-HBc positive/HBsAg negative patients with HIV infection by applying a highly sensitive digital droplet PCR assay |
Poster: Cancers in HIV
P 8 The multidisciplinary group for HPV related disease and STD in Azienda Ospedaliera Universitaria Pisana (AOUP) Cisanello. An opportunity for HIV and HIV at risk people |
P 9 Non-AIDS-defining cancers in a cohort of HIV positive patients |
P 10 Case report on oncopathology in HIV-infected patients |
P 11 Primitive NHL of bone in an HIV patient: case-report and review of literature |
P 12 Alexithymia and cancer-related mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study |
P 14 Oral Human Papillomavirus (HPV) detection in the context of the multidisciplinary HPV group in Azienda Ospedaliero-Universitaria Pisana (AOUP): a screening opportunity for HIV+ and other at risk-patients |
P 15 HCC Recurrence 8 years post Liver-Transplant was linked to Hepatitis Delta Reactivation in a person living with HIV |
P 16 Epidemiological analysis from a newly established anal HPV screening ambulatory |
Poster: Gender issues
P 17 Behavioural and awareness changes in a HIV prevention program based on women empowerment in Uganda |
P 18 Therapy burdens of Italian women living with HIV - Findings from the Positive Perspectives 2 Study |
P 19 Transgender people and HIV |
P 20 HIV-positive transgender people in follow-up at an Italian single tertiary care hospital in Florence: a cross-sectional study |
P 21 HPV and bacterial vaginal infection impact on immune system in a cohort of HIV female population under suppressive ART |
Poster: HCV elimination
P 22 Qualitative analysis of significant clinical events in a cohort of patients after DAA treatment for chronic HCV infection after virological eradication |
P 23 A fast track city micro-project to eradicate HCV infection in PLWHIV |
P 24 A pilot intervention for HCV elimination among MSM in Rome: preliminary results |
P 25 HCV eradication in people living with HIV in Sassari: the final countdown? |
P 26 Glecaprevir/Pibrentasvir and Sofosbuvir/Velpatasvir/Voxilaprevir failure in a young man with genotype 1a congenital HCV infection: a case presentation |
P 27 Acute hepatitis C treatment with direct antiviral agents (DAAs) in patients with solid organ cancer |
P 28 How to eliminate HCV in people who inject drugs? Preliminary results of a provincial multi-targeted approach involving three different settings: addictions services, prison, outreach mobile unit for active users |
P 29 Innovative procedures for micro-elimination of HCV infection in persons who use drug (PWUD) |
P 30 Short course therapy for chronic hepatitis C infection |
P 31 DAA failure in HCV genotype 3: virological features and efficacy of re-treatment |
P 32 Therapy of Hepatitis C in Prison: Experience of Systematic Treatment Program in Rome |
P 33 Five years real-life experience with direct-acting antivirals for hepatitis C in a suburban setting in Rome: a retrospective analysis |
P 34 Association Between Polymorphism in the Enhancer Gene and Hepatitis C Virus-induced Hepatocellular Cancer Risk |
P 35 Genotyping and treatment issues with unusual 1e and 1g HCV subtypes from African subjects: report of two cases |
P 36 Feasibility and impact of HCV treatment in a HRS in Milan |
P 37 An effective strategy to achieve HCV micro-elimination: HCV test and treatment into two Harm Reduction Services in Milan |
P 38 Long follow up of monocyte-macrophage immuneactivation markers in HCV mono-infected patients undergoing DAA treatment |
P 39 EradichiamoCi: HCV micro-eradication project among 5 psychoactive substances user services using a DAA delivery strategy |
P 40 Effect of direct antiviral therapy against HCV on CD4+ T cell count in patients with HIV-HCV coinfection |
P 41 HCV treatment in PWID: a linkage to care model in Cagliari |
Poster: Hepatitis epidemiology
P 42 Hepatitis A: has the outbreak ended? |
P 43 Re-treatment of HCV infection following failure to DAAs: data from the SCOLTA cohort |
P 44 HEV in Southern Italy. Still a chimera? |
P 45 Evaluation of early HCC occurrence rate and its risk factors in HCV patients treated with direct-acting antivirals |
Poster: HIV and COVID
P 46 Covid-19 in patients with HIV-1 infection: a single-centre experience in Northern Italy |
P 47 A case of acute hepatitis C in a patient with HIV, occult HBV and SARS-CoV-2 co-infection |
P 48 SARS-CoV-2 infection in a highly-experienced person living with HIV |
P 49 SARS-CoV-2 infection in a HIV+ patient on darunavir-based ART monotherapy: a case report |
P 50 COVID-19 in people living with HIV (PLWH): clinical picture, viral clearance, cellular and antibody response in a case series of a reference HIV/AIDS center in a COVID Hospital in Rome |
P 51 Clinical course and viroimmunological impact of COVID-19 in HIV infected patients: a single-center report from Milan, Italy |
P 52 Management of emergency COVID-19 in prison, Monza experience |
P 53 Psychological impact and awareness of COVID-19 in young people with HIV |
P 54 Review of lopinavir and darunavir use in SARS-CoV-2 and HIV co-infection: is it time to find another role and another actor? |
P 55 Seroprevalence of SARS-CoV2 antibodies in paediatric HIV patients |
Poster: HIV and nervous system
P 56 Study of the types of the nervous system based on temperaments of HIV-infected patients |
P 57 Persistent activation of CXCL13 axis in the Cerebrospinal fluid of People Living with HIV despite Central Nervous System Viral Suppression |
P 58 Limited health literacy (HL) ability and low awareness of HL difficulties in people living with HIV |
P 59 Evolution of cognitive performance at a 2 years follow-up in a group of HIV-infected patients |
P 60 Cerebrospinal fluid viral replication and burden of resistance in HIV-1-infected people with multidrug resistance treated with Ibalizumab |
P 61 In Vitro Effect of Efavirenz on Cultured Primary Astrocytes: Analysis of Neurotoxicity and Matrix Metalloproteinase Inhibition |
P 62 Evaluation of Patient-Reported Outcomes (PROs) and cognitive performance in HIV naïve patients with advanced disease: results from the PRO-Advance study |
P 63 Cerebrospinal Fluid anti-EBV Viral Capsid Antigen IgG Production associates with poorer Performance in Attention, Memory and Executive functions domains among People living with HIV |
P 64 Cryptococcal meningitis in a young woman HIV late presenter: a case report |
Poster: HIV cure
P 65 A multidisciplinary approach to imprint a successful long term adherence skill to Antiretroviral Therapy in naive patients: background and preliminary data of a pilot project of the GLAD group |
P 66 Switching Dolutegravir/Abacavir/Lamivudine single tablet regimen (STR) to a less-costly multi-tablet regimen of Dolutegravir+Abacavir/Lamivudine (generic) in the setting of virologic suppression: data at 48 weeks |
P 67 Complementary-alternative medicines and self prescribed drugs use in women living with HIV |
Poster: HIV epidemiology and retention in care
P 68 Availability of rapid HIV self-test in Italian pharmacies: a survey |
P 69 REducing LAte Presenters Patients rate in Milan area (RELAPP Study): preliminary results |
P 70 May administering routine HIV test be useful to uncover the iceberg in a University Hospital setting? Our experience |
P 71 High rates of lost-to-follow-up among naive HIV+ female population: real-life data from UOC "Immunodeficienze e Malattie Infettive di Genere", D. Cotugno Hospital, Naples, 2017-19 |
P 72 Risk Factors for Late HIV Presentation in a Tertiary Care University Hospital |
P 73 Epidemiology and clinical characteristics of HIV/AIDS among foreign in Campania Region, 2008-19: which differences with Italian population? |
P 74 The efficacy of cART regimens and retention in care in an HIV-infected cohort of naïve patients |
P 75 Characterization of HIV-1 transmission dynamics in North and Central Italy over the years 2012-2019 |
P 76 "EXTERNA": QoL Perception in PLWHIV during ID checkup |
P 77 HIV screening in migrant population living in "ghetti" in Apulia |
P 78 Geographic distribution of delayed presentation of HIV infection in HIV Emilia Romagna Surveillance System |
P 79 Immunological evolution of a cohort of HIV-2 infected patients: peculiarities of an underestimated infection |
P 80 HIV testing offer and services to improve linkage to Care in public services for HIV test: a survey |
P 81 Gap in care and loss to follow up due to administrative barriers among migrants living with HIV in the city of Padova |
P 82 Long-term survivors in a cohort of HIV+ patients diagnosed between 1985 and 1994: predictive factors associated with more than 25 years of survival |
P 83 New diagnoses of HIV infection: what has changed in 10 years |
Poster: HIV immunology and immune-based therapies
P 84 Acne vulgaris as possible Immune Recovery Folliculitis driven by the lymphocyte T CD8+ immunological recovery in naïve and experienced patients |
P 85 Influence of HLA haplotype on immunological recovery in HIV-infected patients |
Poster: HIV pathogenesis
P 86 Oxidative Stress and gut microbiota composition in primary HIV infection |
Poster: HIV prevention (PrEP and PEP)
P 87 PrEP awareness and attitudes in a survey among Italianclinicians |
P 88 PrEP: the stories about who used the therapy |
P 89 Young People Inform Young People - Speak to the students with the Peer Section of the School Project |
P 90 Problems and difficulties in the management of a PrEP clinic |
P 91 Post-exposure prophylaxis in real life |
P 92 Determinants of drug start, schedule change and discontinuation in PrEP users |
P 93 No increased risk of adverse events and sexually transmitted infections in PrEP users despite the rise in condomless sex |
P 94 PreP: psychological and emotional aspects |
P 95 PrEP use amongst MSM in Italy: data from the EMIS 2017 survey |
P 96 Pre-Exposure Prophylaxis (PrEP): the one-year experience of the first dedicated service of Tuscany Region in S.M.Annunziata Hospital, Florence |
P 97 In vitro effect of Castanea Sativa Mill. bark extract (ENC®) on HIV-1 infection: a potential microbicide |
Poster: HIV virology
P 98 Undetectable versus low level HIV viremia on patients taking antiretroviral therapy |
P 99 Quantification of total HIV-1 DNA in the peripheral blood of naïve and treated patients |
P 100 HIV2-Vpx modulation of MDDCs-CD4+ T cells HIV-1 Trans Infection |
P 101 New potential anti-HIV agents: the antimicrobial peptide Temporin L |
P 102 Fast and sensitive qPCR assay for the concomitant quantification of bacterial 16S rDNA and HIV-1 DNA: preliminary data from blood samples of HIV-1 infected patients |
P 103 HIV-DNA quantification in PBMC: evaluation of two new real-time PCR commercial test |
P 104 Influence of HIV-1 V2 domain characteristics on immunological recovery under ART |
P 105 Susceptibility to HIV-1 integrase inhibitors in HIV-1 sub-subtype A6 isolates |
P 106 Residual phenotypic susceptibility to second generation NNRTI in multidrug resistant HIV-1 from the PRESTIGIO Registry |
P 107 In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations |
P 108 Does HLA-C binding stability affect HIV-1 infection? |
P 109 Genotipic Resistance test in rapid ART era |
Poster: HIV-associated tuberculosis
P 110 Tuberculous and non tuberculous mycobacterial extra-pulmonary infections in HIV |
Poster: Issues on antiretroviral therapy
P 111 Short-Cycle Therapy comprising a lamivudine and dolutegravir regimen of 5 days on and 2 off in a small cohort of suppressed HIV-infected patients |
P 112 Are 2-drug regimens with lamivudine plus boosted-PI still a feasible option in the era of integrase inhibitors? A multicenter analysis |
P 113 HIV-DNA decay in ART-naïve patients starting a DTG-based dual vs triple therapy |
P 114 Side effects detected in HIV-positive patients depending on the ART regimen |
P 115 Safety and tolerability of tenofovir alafenamide (TAF) on bone mineralization and renal function in a cohort of young adults with HIV infection |
P 116 A rare case of acute tubular necrosis tenofovir alafenamide-related |
P 117 New cases of diabetes dolutegravir-associated in HIV patients: a case series |
P 118 Reduced Bone catabolism and inflammation in patients switching to TAF-containing cART |
P 119 Viral outcome on tailored treatment strategyusing cost saving antiretroviral (ARV) |
P 120 The need for reducing both ARV and medicine-taking burdens among Italian PLHIV - Findings from the Positive Perspectives 2 Study |
P 121 Switch to darunavir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-infected patients not receiving protease inhibitors-based regimens |
P 122 Nevirapine-based therapy in the twenty-first century: still an effective and safe long-term choice |
P 123 Switch to dual therapy (3tc+dtg or rpv+dtg) in a cohort of people living with HIV: experience from real life |
P 124 Changes in lipid profile and subclinical atherosclerosis after switching to tenofovir alafenamide (TAF) containing antiretroviral regimens in people living with HIV |
P 125 An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control, reducing low level viral replication and continuing immunological recovery in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study) |
P 126 Efficacy of dolutegravir versus darunavir in first-line regimens according to resistance mutations and viral subtype |
P 127 Switch to dolutegravir-based dual therapy: outcomes in ART-experienced patients |
P 128 Evaluation of efficacy and durability of raltegravir once-daily: real-life data from an Italian Center |
P 129 Impact on CD4 count and CD4/CD8 ratio of 3 different integrase inhibitor-based regimens in naïve and experienced patients |
P 130 Alteration of serum lipid profiles in HIV/HCV co-infected patients under treatment with HAART/DAAs combined therapy |
P 131 Plasma viral load decay in first-time INSTI-users. A comparison between raltegravir, elvitegravir/cobicistat and dolutegravir |
P 132 Metabolic profile changes after switching from a PI- to an INI-based regimen in the maintenance treatment of HIV infection |
P 133 Evaluation of lipid profile in HIV naive patients, treated by TAF-based regimens |
Poster: Management and treatment of viral hepatitis
P 134 Younger Age, Male Gender and HCC presence are Associated to anti HCV-DAA failure |
P 135 Reactivation of occult HBV infection in HIV patients treated with direct-acting antivirals for chronic hepatitis C: a retrospective study |
P 136 DAA failure in HCV genotype not 1: virological features and efficacy of re-treatment |
P 137 Virological features and efficacy of re-treatment in HCV patients: a real experience in Southern Italy |
P 138 Overall survival at 3, 5 and 10 years of HIV-positive patients who underwent liver transplantation at the University Hospital of Ancona |
P 139 Viro-immunological and histological characterization of a case of HBV-related hepatitis with immune reconstitution inflammatory syndrome after treatment initiation for HBV/HIV-1 co-infection with bictegravir/emtricitabine/tenofovir alafenamide |
P 140 Indirect hyperbilirubinemia and jaundice during chronic hepatitis C in an HIV-infected patient treated with glecaprevir/pibrentasvir (GLE/PIB) and antiretroviral therapy (ART). The first reported case in Italy |
P 141 Current management of hepatitis B in sclerosis patients treated with disease-modify therapies |
Poster: Management of HIV infection
P 142 Effect of 12-week physical activity program on sarcopenia measures in people living with HIV |
P 143 Reasons for starting D/C/F/TAF and characteristics of patients enrolled in an Italian non-interventional study: the DIAMANTE (TMC114FD1HTX4011) study |
P 144 HIV-1 DNA quantification: Comparative analysis and validation of two commercial qPCR assays |
P 145 Intestinal Alkaline Phosphatase levels in HIV infected patients |
P 146 Diagnostic performance of different screening strategies for the prevention of HPV-related anal cancer |
P 147 Syphilis in newly HIV-1 diagnosed from 2010 to 2019: a single center report |
Poster: Non infectious comorbidities in HIV
P 148 3TC+DTG versus FTC/TAF plus an integrase inhibitor: comparing changes in bone mineral density |
P 149 HTA analysis of glatiramer and neuroprotection in HIV-related comorbidities |
P 150 Low Vitamin D concentration is associated with NAFLD and metabolic syndrome in HIV-1-infected patients on combination antiretroviral therapy |
P 151 Cardiovascular disease risk markers in a small cohort of HIV-infetcted patietns switched from abacavir/lamivudine/dolutegravir to lamivudine plus dolutegravir |
P 152 Prevalence and incidence of Hepatic Steatosis in SCOLTA cohort |
P 153 Factors associated with immunosenescence during early adulthood in HIV-infected patients after durable efficient cART |
P 154 Metabolic changes in HIV-infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: a randomized study (Be-OnE Study) |
P 155 A structured smoking cessation intervention in a single centre in patients living with HIV |
P 156 Physical activity levels in HIV+ cohort of Pavia |
P 157 Machine learning vs Knowledge based approach in health outcomes' prediction in HIV |
P 158 Use of two drugs regimens (2DR) in a cohort of HIV-infected geriatric patients (GEPPO cohort) |
P 159 Poor concordance between liver stiffness and non-invasive fibrosis scores in HIV-1 monoinfected virologically suppressed patients |
P 160 Obesity and overweight among people living with HIV in the province of Pavia: a cross-sectional study |
P 161 Evaluation of resting energy expenditure and body mass composition in a cohort of HIV infected patients on antiretroviral treatment |
P 162 Archi-Prevaleat project. A National Register of color-Doppler ultrasonography of the epi-aortic vessels in Patients Living with HIV |
Poster: Pediatric, adolescent, maternal, fetal aspects
P 163 Rethinking the necessity of intrapartum zidovudine administration. A small case series from a single centre in the north of Italy |
Poster: Pharmacology, pharmacogenomics and drug interactions
P 164 Antiviral activity of 1-(41-chlorophenyl)-4-(42-methylphenyl)-5,6,7,8-tetrahydro-2a,4a-diazacyclopenta[cd]azulene-2-carboxylic acid derivatives |
P 165 Antiviral activity of of 6-(4-methylbenzyl)-3-arylamino-4н-[1,2,4]triazin-5-оne derivatives against yellow fever |
P 166 Dolutegravir, emtricitabine/tenofovir alafenamide fumarate absorption in a gastrectomized HIV-positive patient |
Poster: Social and behavioural science, marginalized groups, community aspects and community surveys
P 167 A survey as a chance of education on U=U in Italian general population |
P 168 Development and management of a web-based system able to collect and analyse data about self-diagnostics HIV test - ULISSE |
P 169 HIV prescriptivetrend 2018 vs 2019 in a teaching hospital in Rome |
P 170 HAARTisticamente An unusual fashion show |
P 171 "La prevenzione va in tournèe" a social experiment and on the field experience on HIV/STIs and social integration |
P 172 Mono-symptomatic therapeutical group for Chemsex users - an ongoing experience |
P 173 HIV rapid testing outside healthcare facilities: diagnostic and educational tool |
P 174 Changes in causes of death of people living with HIV in a large teaching hospital in Rome |
P 175 The PLWH perception of long acting injectable therapy |
P 176 Cohort observational study and HIV brochure in a teaching hospital in Rome |
P 177 HIV Self-Testing in Italy: a usability survey of clients using self-tests at two community organisations |
P 178 Counselling and HIV rapid test for marginalized groups: data from an Emilia-Romagna Region project* |
P 179 School and HIV. Cognitive and Emotional aspects for effective communication |
P 180 Sardinia, first ever institutional Hiv testing and TasP promotion campaign: the communication strategy of Lila Cagliari team |
P 181 "TEST WITH THE STAR": a pre-counselling "dog assistance" pilot project during HIV-HCV screening campaign "1st December World AIDS Day. Communities make the difference. Union makes the difference! HIV LATINA CHALLENGE 2019. U = U" |
P 182 Test, condom and chems: how the habits of people in Milan change. A test experience in a premise |
P 183 Coming out surrealista |
P 184 App as tool for Prevention among students: the launch of a new counselling service about HIV/STIs promoted by Anlaids Onlus |
P 185 PrEP between desire and needing: 2020 update |
P 186 Free anonymous HIV Testing and linkage to care activities: data from the Milano Check Point |
P 187 Pleasure and sociality as drivers of chemsex among Italian gay men living with HIV |
P 188 The multidisciplinary (MD) HPV group in Azienda Ospedaliera Universitaria Pisana (AOUP). Impact of HIV-HPV sinergy. Preliminary data analysis |
P 189 HIV and STIs amongst MSM in Italy: data from the EMIS 2017 survey |
P 190 Never Infected. Perception of the Risk of HIV Infection in Case of Undetectable Virus |
P 191 Linkage to care in HIV: the point of view of people with recent diagnosis |
P 192 AIDS and other sexually transmitted diseases: what do young people know? - a Cross Sectional Study |
P 193 Prevalence and risk factors associated with new diagnosis of STI in individuals attending an in-hospital STI clinic |
P 194 SRHR Sensitization and Education activities from Medical Students |
P 195 "Senza la C" - HCV diagnosis and treatment for people who inject drugs in a community-based setting: results from an experience in Bologna |
P 196 WE TEST - National community-based HIV prevention program |
Poster: Vaccines
P 197 Anti-body response to pneumococcical vaccination in HIV patient after supplementation with probiotic |
P 198 Adherence to the influenza vaccination campaign: experience of a large clinical center |
P 199 HPV oral infection and clearance in Men who have Sex with Men and Transgender Women undergoing nonavalent vaccination: preliminary results from an interventional study |
P 200 Immunization status in a pediatric transplanted cohort: the Federico II teaching hospital experience |
P 201 Vaccination knowledge, attitudes and practices in patients with HIV: a cross-sectional survey |
P 202 Success rate and evolution of immunological parameter over first vaccination against HBV with Fendrix© in People Living with HIV |
P 203 Organization of a dedicated vaccination service for HIV-positive patients, Pre-Exposure Prophylaxis (PrEP) users, and patients in care for sexually transmitted infections (STIs): the experience of S.M.Annunziata Hospital, Florence |
Poster: Cancers in HIV
P 13 Kaposi Sarcoma among AIDS-presenters in Modena: could it be a cluster? |
|
Pre-Conference advanced course
New frontiers in medical virologyPre-Conference advanced course
New challenges in sexually transmitted infections: sexual health, prevention and morePre-Conference advanced course
Nurse management of patients with comorbiditiesSatellite Symposium
Durable treatment success in HIVPlenary Room
ICAR 2020 Opening Session
16.45 - 17.00: Introducing ICAR 2020 and Welcome Addresses
17.00 - 17.15: RaccontART HIV contest Awards
17.15 - 18.15: Keynote Lectures
18.15 - 18.30: Closing Remarks
14.00-15.00 | Pre-Conference advanced course New frontiers in medical virology |
|||||||||||||||||
|
||||||||||||||||||
15.00-16.00 | Pre-Conference advanced course New challenges in sexually transmitted infections: sexual health, prevention and more |
|||||||||||||||||
|
||||||||||||||||||
16.00-16.45 | Satellite Symposium Durable treatment success in HIV |
|||||||||||||||||
|
||||||||||||||||||
16.45-18.30 |
ICAR 2020 Opening Session 16.45 - 17.00: Introducing ICAR 2020 17.00 - 17.15: RaccontART HIV contest Awards 17.15 - 18.15: Keynote Lectures 18.15 - 18.30: Closing Remarks |
|||||||||||||||||
|
||||||||||||||||||
15.00-16.00 | Pre-Conference advanced course Nurse management of patients with comorbidities |
|||||||||||||
|
Plenary Room
Keynote LectureSymposium
Virus persistence and host interactionsSatellite Symposium
Fighting multi drug resistance - the right moment, the right drugsExpert Meeting
Hepatitis C Elimination: the winning challenge of the 8-weeks treatmentOral Communications
Social SciencePlenary Room
Keynote LectureSymposium
New metabolic challenges in comorbiditiesSponsored Symposium
Streamline ART from the start: the novel approach of 2DR single pill regimen dolutegravir/lamivudineOral Communications
Antiretroviral TherapyOral Communications
HIV PreventionPlenary Room
ICAR-CROI Awards 2020 for young Italian HIV investigators14.30-14.50 | Keynote Lectures | |||||||||||||
|
||||||||||||||
15.00-15.55 | Symposium Virus persistence and host interactions |
|||||||||||||
|
||||||||||||||
16.00-17.00 | Satellite Symposium Fighting multi drug resistance - the right moment, the right drugs |
|||||||||||||
|
||||||||||||||
17.00-17.20 | Keynote Lectures | |||||||||||||
|
||||||||||||||
17.30-18.25 | Symposium New metabolic challenges in comorbidities |
|||||||||||||
|
||||||||||||||
18.30-19.30 | Sponsored Symposium Streamline ART from the start: the novel approach of 2DR single pill regimen dolutegravir/lamivudine |
|||||||||||||
|
||||||||||||||
19.30-20.30 | ICAR-CROI Awards 2020 for young Italian HIV investigators |
15.00-16.00 | Expert Meeting Hepatitis C Elimination: the winning challenge of the 8-weeks treatment |
|||||||||||||
|
||||||||||||||
16.00-17.00 | Oral Communications Social Science |
|||||||||||||
|
||||||||||||||
17.30-18.30 | Oral Communications Antiretroviral Therapy |
|||||||||||||
|
||||||||||||||
18.30-19.30 | Oral Communications HIV Prevention |
|||||||||||||
|
17.30-18.30 | Special event Meet the Expert |
|||||
|
Plenary Room
Keynote LectureSponsored Symposium
POP ART (population on ART): from patient to personas A new approach to fulfill PLHIV expectationsSymposium
Reaching out: same models for different infectionsOral Communications
VirologySatellite Symposium
Recent advances in the management of Gram positive infections: the evolving role of long acting therapyPlenary Room
Keynote LectureSatellite Symposium
Committed globally to fight HIV and other severe infectionsSymposium
Lights and shadows in HIV clinical researchOral Communications
ComorbiditiesOral Communications
Clinical Hepatitis and Coinfections14.30-14.50 | Keynote Lectures | |||||||||||
|
||||||||||||
15.00-16.00 | Sponsored Symposium POP ART (population on ART): from patient to personas A new approach to fulfill PLHIV expectations |
|||||||||||
|
||||||||||||
16.00-16.55 | Symposium Reaching out: same models for different infections |
|||||||||||
|
||||||||||||
17.00-17.20 | Keynote Lectures | |||||||||||
|
||||||||||||
17.30-18.30 | Satellite Symposium Committed globally to fight HIV and other severe infections |
|||||||||||
|
||||||||||||
18.30-19.25 | Symposium Lights and shadows in HIV clinical research |
|||||||||||
|
15.00-16.00 | Oral Communications Virology |
|||||||||||||
|
||||||||||||||
16.00-17.00 | Satellite Symposium Recent advances in the management of Gram positive infections: the evolving role of long acting therapy |
|||||||||||||
|
||||||||||||||
17.30-18.30 | Oral Communications Comorbidities |
|||||||||||||
|
||||||||||||||
18.30-19.30 | Oral Communications Clinical Hepatitis and Coinfections |
|||||||||||||
|
17.30-18.30 | Special event Meet the Expert |
|||||
|
Plenary Room
Round Table: HIV in COVID-19 era: how to ensure quality of care and outpatient managementSatellite Symposium
HIV: understanding the real burdens of the diseaseSymposium
Immune control over HIV reservoirSymposium
Challenges in PrEP implementation and TasP confidenceSymposium
HIV and Coinfections: new challenges for 2020Oral Communications
Basic Science and ImmunologyExpert Meeting
Enhancing care for people living with HIV: current and future of monitoring approachesOral Communications
Clinical HIVExpert Meeting
Urgent global challenges in infectious diseases: fight together against HIV and AMR14.30-15.15 | Round Table: HIV in COVID-19 era: how to ensure quality of care and outpatient management | |||||||||||||
|
||||||||||||||
15.20-16.20 | Satellite Symposium HIV: understanding the real burdens of the disease |
|||||||||||||
|
||||||||||||||
16.20-17.15 | Symposium Immune control over HIV reservoir |
|||||||||||||
|
||||||||||||||
17.20-18.15 | Symposium Challenges in PrEP implementation and TasP confidence |
|||||||||||||
|
||||||||||||||
18.20-19.25 | Symposium HIV and Coinfections: new challenges for 2020 |
|||||||||||||
|
15.20-16.20 | Oral Communications Basic Science and Immunology |
|||||||||||||||
|
||||||||||||||||
16.20-17.20 | Expert Meeting Enhancing care for people living with HIV: current and future of monitoring approaches |
|||||||||||||||
|
||||||||||||||||
17.20-18.20 | Oral Communications Clinical HIV |
|||||||||||||||
|
||||||||||||||||
18.20-19.20 | Expert Meeting Urgent global challenges in infectious diseases: fight together against HIV and AMR |
|||||||||||||||
|
17.20-18.20 | Special event Meet the Expert |
|||||
|
Symposium
The Fast-Track Cities initiative and the Italian state of the artSymposium
ART treatment: when the patient's journey becomes difficultSymposium
Proud to be women, proud to fight HIVOral Communications
ImmunopathogenesisOral Communications
Hepatitis and Clinical VirologyOral Communications
Social Science and EpidemiologyOral Communications
PharmacologyPlenary Room
ICAR 2020 Special AwardsPlenary Room
ICAR 2020 Closing remarks14.30-15.15 | Symposium The Fast-Track Cities initiative and the Italian state of the art |
|||||||||||
|
||||||||||||
15.20-16.20 | Special event Special Session on HIV and COVID in Italy |
|||||||||||
|
||||||||||||
16.20-17.15 | Symposium ART treatment: when the patient's journey becomes difficult |
|||||||||||
|
||||||||||||
17.20-18.15 | Symposium Proud to be women, proud to fight HIV |
|||||||||||
|
||||||||||||
16.45-17.00 | ICAR 2020 Special Awards | |||||||||||
|
||||||||||||
18.35-18.45 | Symposium Closing remarks |
|||||||||||
|
15.20-15.50 | Oral Communications Immunopathogenesis |
|||||||||||||
|
||||||||||||||
15.50-16.20 | Oral Communications Hepatitis and Clinical Virology |
|||||||||||||
|
||||||||||||||
16.20-17.20 | Oral Communications Social Science and Epidemiology |
|||||||||||||
|
||||||||||||||
17.20-18.20 | Oral Communications Pharmacology |
|||||||||||||
|
■ Plenary session
■ Special events session
■ Pre-Conference courses session
■ Symposium session
■ Oral Communications session
■ Oral Poster session
■ Sponsored session